Pumitamig Plus Docetaxel Shows 36.7% ORR, 6.9-Month PFS in 2L NSCLC
BNTX is trading near its 52-week low of $79.52 (8.0% above the low).
Summary
BioNTech and Bristol Myers Squibb reported Phase 2 ROSETTA Lung-107 data showing pumitamig plus docetaxel produced a 36.7% confirmed response rate and 6.9-month median PFS in second-line NSCLC, with a manageable safety profile.
Key Events · Product Development and Regulatory · BNTX
-
Phase 2 Pumitamig Data in 2L NSCLC
ROSETTA Lung-107 evaluated pumitamig 1400 mg plus docetaxel in 50 patients with metastatic NSCLC progressing after first-line immunotherapy plus chemotherapy; data presented at ESMO 2026.
-
36.7% Confirmed Response Rate
Among 30 efficacy-evaluable patients, confirmed ORR was 36.7% with a 90.0% disease control rate; responses seen across PD-L1 levels and both squamous (57.1%) and non-squamous (30.4%) histologies.
-
6.9-Month Median PFS vs ~3.6-3.9 Months
Median PFS was 6.9 months (95% CI 4.2-not reached) with a six-month PFS rate of 63.3%, versus historical docetaxel median PFS of approximately 3.6-3.9 months in this setting.
-
Manageable Safety, No New Signals
Grade >=3 treatment-related adverse events occurred in 18.0% of patients, with no pumitamig-related deaths or dose-limiting toxicities; four patients (8.0%) discontinued treatment.
Analysis · BNTX · Life Sciences
BioNTech and BMS have reported the third global Phase 2 dataset for pumitamig, now extending into second-line NSCLC after immunotherapy plus chemotherapy—a setting where docetaxel has been standard of care with median PFS of roughly 3.6-3.9 months. A 36.7% confirmed response rate and 6.9-month median PFS are encouraging, but this is a single-arm 50-patient trial with immature survival data, so it supports the broad Phase 3 program rather than proving a registrational benefit. The readout matters because pumitamig is one of BioNTech's key oncology bets while its revenue base shrinks after the 2026 guidance cut.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BNTX was trading at $85.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.1B. The 52-week trading range was $79.52 to $124.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.